Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Select A Multi-centre Randomised Prospective Open-label Study to Investigate the Efficacy & Safety of a Standardised Correction Dosage Regimen of i.v. Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease

NCT00810030 is registered in ClinicalTrials.gov with Vifor Pharma as lead sponsor.

NCT NCT00810030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00810030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Select A Multi-centre Randomised Prospective Open-label Study to Investigate the Efficacy & Safety of a Standardised Correction Dosage Regimen of i.v. Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease
Lead sponsor
Vifor Pharma
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2008
Completion date
April 30, 2010
Enrollment
484 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, crohn's disease, inflammatory bowel disease, iron deficiency, iron-deficiency anemia, ulcerative colitis